drugset / Trial / NCT07564401
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136.
Timeline
- Start
- 2026-06-16
- Primary completion
- 2031-03-03
- Completion
- 2031-03-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DJI136 | Cell therapy | — | Intravenous |